Lisata Therapeutics Reaches Agreement With EMA On Paediatric Investigation Plan For Lead Product Certepetide In Pancreatic Cancer; Receives Full Pediatric Waiver
Portfolio Pulse from Benzinga Newsdesk
Lisata Therapeutics has reached an agreement with the European Medicines Agency (EMA) on a Paediatric Investigation Plan for its lead product, Certepetide, in pancreatic cancer. The company has also received a full pediatric waiver.
May 20, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lisata Therapeutics has secured an agreement with the EMA on a Paediatric Investigation Plan for Certepetide in pancreatic cancer and received a full pediatric waiver.
The agreement with the EMA and the full pediatric waiver are significant regulatory milestones for Lisata Therapeutics. This could positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100